{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:33:26Z","timestamp":1792035206817,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["U01AA021886"],"award-info":[{"award-number":["U01AA021886"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.cld.2024.06.014","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T05:31:18Z","timestamp":1722490278000},"page":"747-760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging Pharmacologic Treatments for Alcohol-Associated Hepatitis"],"prefix":"10.1016","volume":"28","author":[{"given":"Timothy R.","family":"Morgan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2024.06.014_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.cld.2024.06.005","article-title":"Pathogenesis of alcohol-associated liver disease","author":"Mandrekar","year":"2024","journal-title":"Clin Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2024.06.014_bib2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American association for the study of liver diseases","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1","key":"10.1016\/j.cld.2024.06.014_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"Electronic address eee, European association for the study of the L. EASL clinical practice guidelines: management of alcohol-related liver disease","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2024.06.014_bib4","article-title":"Current medical treatment of alcohool-associated liver disease: pharmacological and nutrition","author":"McClain","year":"2024","journal-title":"Clin Liver Dis"},{"issue":"5","key":"10.1016\/j.cld.2024.06.014_bib5","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s12072-020-10082-6","article-title":"Interleukin-22 in alcoholic hepatitis and beyond","volume":"14","author":"Xiang","year":"2020","journal-title":"Hepatology International"},{"issue":"1","key":"10.1016\/j.cld.2024.06.014_bib6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/hep.24339","article-title":"In\u00a0vivo consequences of liver-specific interleukin-22 expression in mice: implications for human liver disease progression","volume":"54","author":"Park","year":"2011","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"4","key":"10.1016\/j.cld.2024.06.014_bib7","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/hep.23837","article-title":"Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3","volume":"52","author":"Ki","year":"2010","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"4","key":"10.1016\/j.cld.2024.06.014_bib8","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jhep.2019.11.013","article-title":"Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice","volume":"72","author":"Xiang","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2024.06.014_bib9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41423-018-0029-8","article-title":"Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects","volume":"16","author":"Tang","year":"2019","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"10.1016\/j.cld.2024.06.014_bib10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/cpt.1164","article-title":"Randomized phase I healthy volunteer study of UTTR1147A (IL-22Fc): a potential therapy for epithelial injury","volume":"105","author":"Rothenberg","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.cld.2024.06.014_bib11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.31046","article-title":"An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis","volume":"72","author":"Arab","year":"2020","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"9","key":"10.1016\/j.cld.2024.06.014_bib12","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1023\/A:1025463532521","article-title":"Granulocyte-colony stimulating factor administration ameliorates liver regeneration in animal model of fulminant hepatic failure and encephalopathy","volume":"48","author":"Theocharis","year":"2003","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.cld.2024.06.014_bib13","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.exphem.2004.09.005","article-title":"G-CSF-primed hematopoietic stem cells or G-CSF per se accelerate recovery and improve survival after liver injury, predominantly by promoting endogenous repair programs","volume":"33","author":"Yannaki","year":"2005","journal-title":"Exp Hematol"},{"issue":"5","key":"10.1016\/j.cld.2024.06.014_bib14","doi-asserted-by":"crossref","first-page":"100139","DOI":"10.1016\/j.jhepr.2020.100139","article-title":"Granulocyte colony-stimulating factor for alcoholic hepatitis: a systematic review and meta-analysis of randomised controlled trials","volume":"2","author":"Marot","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cld.2024.06.014_bib15","doi-asserted-by":"crossref","first-page":"101689","DOI":"10.1016\/j.eclinm.2022.101689","article-title":"A\u00a0phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis","volume":"54","author":"Tayek","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.cld.2024.06.014_bib16","doi-asserted-by":"crossref","first-page":"100063","DOI":"10.1016\/j.jlr.2021.100063","article-title":"25-Hydroxycholesterol 3-sulfate is an endogenous ligand of DNA methyltransferases in hepatocytes","volume":"62","author":"Wang","year":"2021","journal-title":"J\u00a0Lipid Res"},{"issue":"3","key":"10.1016\/j.cld.2024.06.014_bib17","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1124\/mol.112.081505","article-title":"5-cholesten-3beta,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model","volume":"83","author":"Xu","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.cld.2024.06.014_bib18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.metabol.2016.12.007","article-title":"Cholesterol metabolites alleviate injured liver function and decrease mortality in an LPS-induced mouse model","volume":"71","author":"Ning","year":"2017","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.cld.2024.06.014_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.14309\/ajg.0000000000002275","article-title":"Safety, pharmacokinetics, and efficacy signals of larsucosterol (DUR-928) in alcohol-associated hepatitis","volume":"119","author":"Hassanein","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2024.06.014_bib20","author":"Corporation"},{"issue":"2","key":"10.1016\/j.cld.2024.06.014_bib21","doi-asserted-by":"crossref","first-page":"100220","DOI":"10.1016\/j.jhepr.2020.100220","article-title":"Gut dysbiosis as a driver in alcohol-induced liver injury","volume":"3","author":"Fairfield","year":"2021","journal-title":"JHEP Rep"},{"issue":"5","key":"10.1016\/j.cld.2024.06.014_bib22","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gutjnl-2015-310585","article-title":"Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease","volume":"65","author":"Llopis","year":"2016","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.cld.2024.06.014_bib23","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.cgh.2016.10.029","article-title":"Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study","volume":"15","author":"Philips","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2024.06.014_bib24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12072-022-10438-0","article-title":"Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial","volume":"17","author":"Pande","year":"2023","journal-title":"Hepatology International"},{"issue":"2","key":"10.1016\/j.cld.2024.06.014_bib25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12072-022-10312-z","article-title":"Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial","volume":"16","author":"Sharma","year":"2022","journal-title":"Hepatology International"},{"key":"10.1016\/j.cld.2024.06.014_bib26","doi-asserted-by":"crossref","first-page":"goac074","DOI":"10.1093\/gastro\/goac074","article-title":"Clinical outcomes and gut microbiota analysis of severe alcohol-associated hepatitis patients undergoing healthy donor fecal transplant or pentoxifylline therapy: single-center experience from Kerala","volume":"10","author":"Philips","year":"2022","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"3","key":"10.1016\/j.cld.2024.06.014_bib27","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jhep.2018.10.004","article-title":"Only in the darkness can you see the stars: severe alcoholic hepatitis and higher grades of acute-on-chronic liver failure","volume":"70","author":"Philips","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2024.06.014_bib28","first-page":"8A","article-title":"Three-year follow-up of alcohol-related hepatitis patients undergoing healthy donor fecal transplant: analysis of clinical outcomes, relapse, gut microbiota and comparisons with standard care","volume":"74","author":"Philips","year":"2021","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"7783","key":"10.1016\/j.cld.2024.06.014_bib29","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41586-019-1742-x","article-title":"Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease","volume":"575","author":"Duan","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.cld.2024.06.014_bib30","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/liv.15207","article-title":"Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: a pilot study (RIFA-AH)","volume":"42","author":"Jimenez","year":"2022","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.cld.2024.06.014_bib31","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1365-2036.2009.03958.x","article-title":"Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis","volume":"29","author":"Vlachogiannakos","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.cld.2024.06.014_bib32","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S2468-1253(23)00010-9","article-title":"Rifaximin-alpha for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"8","author":"Israelsen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2024.06.014_bib33","doi-asserted-by":"crossref","first-page":"e0264278","DOI":"10.1371\/journal.pone.0264278","article-title":"The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: a randomized clinical trial","volume":"17","author":"Kimer","year":"2022","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.cld.2024.06.014_bib34","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1101214","article-title":"Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis","volume":"365","author":"Nguyen-Khac","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2024.06.014_bib35","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jhep.2005.11.039","article-title":"Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis--a randomised clinical trial","volume":"44","author":"Phillips","year":"2006","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2024.06.014_bib36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2007.03.027","article-title":"A\u00a0randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis","volume":"47","author":"Stewart","year":"2007","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2024.06.014_bib37","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jhep.2010.05.030","article-title":"Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial","volume":"53","author":"Moreno","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2024.06.014_bib38","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.cgh.2018.01.040","article-title":"Efficacy of granulocyte colony stimulating factor and N-acetyl cysteine therpies in patients with severe alcoholic hepatitis","volume":"16","author":"Singh","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"16","key":"10.1016\/j.cld.2024.06.014_bib39","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.3748\/wjg.v21.i16.4975","article-title":"Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis","volume":"21","author":"Higuera-de la Tijera","year":"2015","journal-title":"World J Gastroenterol : WJG"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932612400062X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932612400062X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T03:47:04Z","timestamp":1729050424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108932612400062X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S108932612400062X"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2024.06.014","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Pharmacologic Treatments for Alcohol-Associated Hepatitis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2024.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}